Moreover, we demonstrate that KDM6A-mediated activation of TRKA is required for protection of CML cells against imatinib afforded by the neurotrophin nerve growth factor (NGF). Here, NGF is linked to chronic myelogenous leukemia, BCR-ABL1 positive.